GlassScriptPhysician profile
Kimberly Myers
NPI 1952839961
$2,639.86
in general payments reported to CMS, 2019-2025
30 companies · $874 in 2025
The $874 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.23 · 2022: $175 · 2023: $587 · 2024: $937 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361 · Education: $35.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.44 |
| Education | $35.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.74 | 2022-2025 | |
| Novo Nordisk INC | $285.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $227.90 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $199.81 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $152.30 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.55 | 2022-2024 | Caplyta |
| Exact Sciences Corporation | $123.80 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $84.09 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $82.22 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $71.57 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $71.18 | 2023-2024 | Gardasil 9, Vaxelis, Rotateq |
| Alkermes, INC. | $60.18 | 2025 | Aristada, Lybalvi |
| Abbott Laboratories | $55.16 | 2023-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.63 | 2022-2025 | Xifaxan |
| Lundbeck LLC | $52.01 | 2024-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.03 | 2022-2023 | Evenity, Prolia, Repatha |
| Abiomed | $46.88 | 2024-2025 | Impella |
| Xeris Pharmaceuticals, INC. | $43.64 | 2023-2024 | Gvoke Hypopen |
| Medtronic, INC. | $41.97 | 2024-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $34.25 | 2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.51 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.33 | 2024 | |
| Idorsia Pharmaceuticals US INC | $21.59 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $17.15 | 2025 | Nexletol |
| Inspire Medical Systems, INC. | $16.97 | 2025 | Inspire |
| Tandem Diabetes Care, INC. | $15.89 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Takeda Pharmaceuticals U.S.A., INC. | $15.78 | 2025 | Trintellix |
| Sanofi Pasteur INC. | $15.56 | 2023 | |
| Ironwood Pharmaceuticals, INC | $15.00 | 2024 | |
| Corium, LLC | $10.99 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.